Sun Pharmaceutical Industries Ltd.

Sun Pharmaceutical Industries is currently trading at Rs. 794.80, up by 10.90 points or 1.39 % from its previous closing of Rs. 783.90 on the BSE.

The scrip opened at Rs. 776.00 and has touched a high and low of Rs. 800.90 and Rs. 776.00 respectively. So far 125581 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 799.45 on 30-Jul-2014 and a 52 week low of Rs. 475.60 on 22-Aug-2013.

Last one week high and low of the scrip stood at Rs. 785.00 and Rs. 743.25 respectively. The current market cap of the company is Rs. 165040.70 crore.

The promoters holding in the company stood at 63.65 % while Institutions and Non-Institutions held 28.05 % and 8.29 % respectively.

Sun Pharmaceutical Industries has reported 4.07% rise in its net profit at Rs 47.56 crore for first quarter ended June 30, 2014 as compared to Rs 45.70 crore for the quarter ended June 30, 2013. The company’s total income has increased by 13.26% to Rs 659.79 crore for the quarter under review from Rs 582.54 crore for the corresponding quarter of the previous year.

On the consolidated basis, the company has reported a net profit after taxes & Minority interest of Rs 1390.51 crore for the quarter as compared to a net loss of Rs 1276.10 crore for the same quarter in the previous year. Its total income has increased by 12.59% at Rs 4027.96 crore for quarter under review as compared to Rs 3577.56 crore for the quarter ended June 30, 2013.

Pursuant to the scheme of arrangement in the nature of demerger, the specified undertaking of Sun Pharma Global FZE, a wholly owned subsidiary, has been transferred into the Company with effect from May 1, 2013, without any consideration, on a going concern basis consisting of all the assets and liabilities pertaining to the said undertaking. The scheme of arrangement has been approved by shareholders of both the companies and is also approved by the High Court of Gujarat. Accordingly, the financial statements for the year ended March 31, 2014, earlier approved by the Board of Directors at their meeting held on May 29, 2014, have been revised and approved by them at their meeting held August 12, 2014. The effect of the Scheme was given in the financial results for the year ended March 31, 2014 only on an annual basis and approved by the Board of Directors at their meeting held on August 12, 2014. However, the financial results for quarterly periods during the year ended March 31, 2014 have not been restated in these results.